Oncology Focus Areas:
Our other therapy areas

    • {%itemName%}
        {%brandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%subBrandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%productMenuItems%}
    • {%itemKeyName%} {%itemBadges%} {%arrowSpan%}
      {%selfProduct%}
    • {%itemName%}
      • {%countries%}
    • {%allMenuItem%}
      • {%languages%}

      • This website is for UK Healthcare Professionals only

      UK-VNCAML-220206. Date of Preparation: November 2022.

      View expert videos

      Resources

      Downloadable materials for HCPs

      Below are links to downloadable materials that may be useful to use as a reference in your routine clinical practice 

      Dosing & Administration guide

      Dosing & Administration guide

      The Dosing & Administration guide gives a brief introduction to the VENCLYXTO mode of action and pivotal VIALE-A clinical trial, as well as information on TLS prophylaxis, dosing and adverse event management.

      UK-VNCAML-230107 | September 2023

      Dosing & Administration booklet

      Dosing & Administration booklet

      The Dosing & Administration booklet provides information on initiating AML patients on VENCLYXTO + azacitidine and includes guidance on TLS prophylaxis and adverse event management.

      UK-VNCAML-220007 | May 2022

      Dosing & Administration poster

      Dosing & Administration poster

      The Dosing & Administration poster provides an overview of TLS prophylaxis and VENCLYXTO + azacitidine dose-ramp up.

      UK-VNCAML-230108 | September 2023

      Downloadable materials for your AML patients prescribed VENCLYXTO

      Below are links to downloadable materials that may be useful to use as a reference in your routine clinical practice 

       

      VENCLYXTO AML patient booklet 

      VENCLYXTO AML patient booklet

      This booklet gives an overview of starting treatment with VENCLYXTO. Inside, patients with their healthcare team can document their treatment initiation plan.

      UK-VNCAML-230093 | September 2023 

      Understanding AML patient booklet

      Understanding AML patient booklet

      This booklet provides an overview of AML and some things to consider after receiving diagnosis of AML.

      UK-VNCAML-230091 | September 2023

      Patient wallet card
       

      Patient wallet card

      This wallet-sized card provides some important details about VENCLYXTO. Patients should be encouraged keep the card with them at all times and present it at any medical appointment they attend.

      UK-VNCAML-230095 | September 2023 

      Patient commonly asked questions

      Patient commonly asked questions

      This booklet discusses commonly asked questions surrounding VENCLYXTO treatment and gives suggestions of questions that patients may want to ask at their appointments. 

      UK-VNCAML-230097 | September 2023

      Downloadable materials for the carers of your patients with AML

      Below are links to downloadable materials that may be useful to use as a reference in your routine clinical practice 

       

      Caregiver booklet
       

      Caregiver booklet

      This booklet is designed for caregivers of people with AML and provides information on the disease, as well as places to seek support. 

      UK-VNCAML-230102 | September 2023

      Caregiver commonly asked questions 

      Caregiver commonly asked questions

      This booklet discusses commonly asked questions surrounding AML and treatment and gives suggestions of questions caregivers may want to ask at appointments.

      UK-VNCAML-230100 | September 2023

      VENCLYXTO AML PRESCRIBING INFORMATION
      VENCLYXTO CLL PRESCRIBING INFORMATION

       

      Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.

      Adverse events should also be reported to AbbVie on [email protected]

      UK-VNCAML-230110. Date of preparation: October 2023.

      Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores. Adverse events should also be reported to AbbVie on [email protected]

       

      This website is for UK Healthcare Professionals only

      UK-ABBV-230225. Date of preparation June 2023. This website has been developed and funded by AbbVie Ltd.

      © 2023 AbbVie Ltd. All rights reserved. Registered Number: 08004972 England.